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BACKGROUND
Embolic strokes of undetermined source represent 20% of ischemic strokes and 
are associated with a high rate of recurrence. Anticoagulant treatment with rivarox­
aban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than 
aspirin.
METHODS
We compared the efficacy and safety of rivaroxaban (at a daily dose of 15 mg) with 
aspirin (at a daily dose of 100 mg) for the prevention of recurrent stroke in patients 
with recent ischemic stroke that was presumed to be from cerebral embolism but 
without arterial stenosis, lacune, or an identified cardioembolic source. The pri­
mary efficacy outcome was the first recurrence of ischemic or hemorrhagic stroke 
or systemic embolism in a time­to­event analysis; the primary safety outcome was 
the rate of major bleeding.
RESULTS
A total of 7213 participants were enrolled at 459 sites; 3609 patients were ran­
domly assigned to receive rivaroxaban and 3604 to receive aspirin. Patients had 
been followed for a median of 11 months when the trial was terminated early 
because of a lack of benefit with regard to stroke risk and because of bleeding 
associated with rivaroxaban. The primary efficacy outcome occurred in 172 pa­
tients in the rivaroxaban group (annualized rate, 5.1%) and in 160 in the aspirin 
group (annualized rate, 4.8%) (hazard ratio, 1.07; 95% confidence interval [CI], 
0.87 to 1.33; P = 0.52). Recurrent ischemic stroke occurred in 158 patients in the 
rivaroxaban group (annualized rate, 4.7%) and in 156 in the aspirin group (an­
nualized rate, 4.7%). Major bleeding occurred in 62 patients in the rivaroxaban 
group (annualized rate, 1.8%) and in 23 in the aspirin group (annualized rate, 
0.7%) (hazard ratio, 2.72; 95% CI, 1.68 to 4.39; P<0.001).
CONCLUSIONS
Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent 
stroke after an initial embolic stroke of undetermined source and was associated 
with a higher risk of bleeding. (Funded by Bayer and Janssen Research and Devel­
opment; NAVIGATE ESUS ClinicalTrials.gov number, NCT02313909.)
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Ischemic strokes of uncertain cause, also called cryptogenic strokes, are frequent despite advances in the diagnostic techniques 
used to determine the underlying cause and to 
implement treatment specific to their causes.1­3 
Most cryptogenic strokes are presumed to result 
from emboli originating from cardiac and arte­
rial sources and occasionally from venous throm­
boembolism due to paradoxical embolism, such 
as those associated with patent foramen ovale. 
For the purposes of clinical trials, the term “em­
bolic stroke of undetermined source” has been 
proposed to describe a group of cryptogenic 
strokes, representing approximately 20% of ische­
mic strokes, that are not associated with proxi­
mal arterial stenosis or a recognized cardioem­
bolic source, such as atrial fibrillation of left 
ventricular thrombus, and that are not lacunar.1
The known efficacy of anticoagulants for the 
prevention of embolic stroke in patients with 
atrial fibrillation4,5 led us to hypothesize that 
anticoagulants would be more effective than anti­
platelet therapy for the prevention of recurrent 
stroke in patients with recent embolic stroke of 
undetermined source.1,6 Rivaroxaban is an orally 
administered, direct factor Xa inhibitor that is 
effective for the prevention of stroke in patients 
with atrial fibrillation. We designed the New 
Approach Rivaroxaban Inhibition of Factor Xa in 
a Global Trial versus ASA to Prevent Embolism 
in Embolic Stroke of Undetermined Source 
(NAVIGATE ESUS) trial to compare rivaroxaban 
with aspirin to test this hypothesis.
Me thods
Trial Design
We conducted this international, randomized, 
event­driven, phase 3 trial at 459 centers in 31 
countries. The rationale for the trial, design de­
tails, and eligibility features have been published 
previously.6,7
Patients were randomly assigned in a 1:1 ratio 
with variable block size, stratified according to 
country and age of the patient (<60 years vs. ≥60 
years), with the use of an interactive Web­ 
response system, to receive either rivaroxaban at 
a dose of 15 mg (immediate­release, film­coated 
tablets) plus placebo or aspirin at a dose of 100 mg 
(enteric coated tablets) plus placebo; in each 
group, the two tablets (active drug and placebo) 
were taken orally once daily. Active medication 
and identical placebos were taken with food; 
adherence to assigned therapy was assessed by 
means of interview and pill counts at each clinic 
visit. Patients returned for outpatient visits at 1, 
6, and 12 months and then every 6 months, dur­
ing which there was assessment for the occur­
rence of safety and efficacy events, adherence, 
and adverse events. Investigators and patients 
were unaware of the treatment assignments dur­
ing the trial.
The trial was conducted and reported in ac­
cordance with the protocol (available with the 
full text of this article at NEJM.org) and the 
statistical analysis plan. The trial was initiated 
by the two principal investigators, who designed 
the trial with input from a steering committee 
(which included representatives of the trial spon­
sors, Bayer and Janssen Research and Develop­
ment). The Population Health Research Institute 
at McMaster University selected the trial sites, 
collected and managed the data, and performed 
the data analysis, with financial support from 
the sponsors. The trial sponsors provided trial 
medications, contracted with and paid the mem­
bers of the steering committee and the trial 
sites, and provided site monitoring.
The two principal investigators wrote the first 
draft of the manuscript. There were no agree­
ments in place with the sponsors concerning the 
confidentiality of trial data. The sponsors com­
mented on the manuscript before submission 
for publication, but sponsor approval was not 
required for submission. The authors vouch for 
fidelity of the trial to the protocol and for the 
accuracy and completeness of the data and the re­
porting of adverse events. The protocol was 
approved by the relevant health authorities and 
the institutional review board at each trial site. 
Written informed consent was obtained from 
each participant.
Trial Population
Patients who had ischemic stroke, as identified 
on cerebral imaging, that had occurred between 
7 days and 6 months before screening were eli­
gible if the stroke was not lacunar and was not 
associated with extracranial vessel atherosclero­
sis causing more than 50% luminal stenosis in 
arteries supplying the area of ischemia or with 
identified risk factors for a cardiac source of 
embolism (atrial fibrillation, left ventricular 
thrombus, mechanical prosthetic cardiac valve, 
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or severe mitral stenosis) and if no other cause 
of stroke could be found.6 Intracranial imaging 
was optional, but if it was performed, a finding 
of more than 50% stenosis due to atherosclero­
sis was an exclusion criterion. Participants had 
to be older than 49 years at the time of the 
stroke; if participants were 50 to 59 years of age, 
they were required to have at least one addi­
tional vascular risk factor (hypertension, diabetes, 
previous ischemic stroke, active tobacco smok­
ing, or heart failure).6
After the qualifying stroke, at least 20 total 
hours of cardiac rhythm monitoring were re­
quired in order to rule out atrial fibrillation last­
ing 6 minutes or longer, although investigators 
could choose to monitor for longer periods. 
Cardiac rhythm monitoring had to be completed 
before randomization, and the presence of im­
plantable loop recorders therefore excluded par­
ticipation. Echocardiography was required, and 
intracardiac thrombus that was detected by either 
transthoracic or transesophageal echocardiogra­
phy was an exclusion criterion. Patients who had 
received a diagnosis of patent foramen ovale 
were eligible for entry to the trial unless there 
were plans for closure of the defect. Additional 
exclusion criteria were a history of atrial fibrilla­
tion, severely disabling stroke (modified Rankin 
score of ≥4 at screening; scores range from 0 to 
6, with higher scores representing worse func­
tional deficits), a specific indication for anti­
coagulation or for antiplatelet therapy, ongoing 
regular use of conventional nonsteroidal antiin­
flammatory drugs, major bleeding within the 
previous 6 months, and previous nontraumatic 
intracranial hemorrhage.
Outcomes
The primary efficacy outcome was the first re­
current stroke (including ischemic, hemorrhagic, 
or undefined stroke) or systemic embolism in a 
time­to­event analysis. Ischemic stroke was de­
fined as a focal neurologic deficit of sudden 
onset that was due to presumed arterial occlu­
sion persisting for more than 24 hours and 
without evidence of primary hemorrhage on 
neuroimaging; if there was a neurologic deficit 
lasting less than 24 hours, evidence of acute 
brain infarct had to be present on neuroimag­
ing.8 Hemorrhagic strokes included symptomat­
ic, nontraumatic intracerebral and subarachnoid 
hemorrhages. Undefined strokes (based on an 
absence of neuroimaging or autopsy features to 
distinguish ischemic from hemorrhagic stroke) 
were considered to be ischemic strokes in the 
analyses unless otherwise noted.
Secondary efficacy outcomes were a compos­
ite of death from cardiovascular causes, recur­
rent stroke, systemic embolism, and myocardial 
infarction; death from any cause; disabling 
stroke (modified Rankin scale score of 4 or 5 at 
hospital discharge) or fatal stroke (modified 
Rankin scale score of 6); and individual compo­
nents of the primary and secondary efficacy 
outcomes. The severity of the stroke at trial entry 
was estimated with the use of the National In­
stitutes of Health Stroke Scale (NIHSS) score 
(scores range from 0 to 42, with higher scores 
representing worse neurologic deficits).
The primary safety outcome was major bleed­
ing at any site in the body according to the cri­
teria of the International Society of Thrombosis 
and Hemostasis (ISTH).9 Secondary safety out­
comes were life­threatening or fatal bleeding, 
clinically relevant nonmajor bleeding, and intra­
cranial hemorrhage (including traumatic and 
atraumatic intracerebral, subarachnoid, and sub­
dural or epidural hemorrhage).
Outcome events were reported by local inves­
tigators through the completion of case­report 
forms that included questions regarding out­
comes and adverse events. Potential outcome events 
that did not meet all the trial protocol criteria 
were adjudicated by stroke experts who were flu­
ent in the language of the participating clinical 
site and who reviewed untranslated source 
documents and, if there was disagreement with 
the local investigator, by the secondary review of 
translated source documents by the chairs of the 
central adjudication committee, all of whom were 
unaware of the treatment assignments.
Statistical Analysis
We planned to enroll 7000 patients and to follow 
them for a mean of 2 years to detect a rate of 
primary efficacy outcome events that was 30% 
lower with rivaroxaban than with aspirin, with 
90% power, on the basis of an estimated rate of 
the primary outcome of 3.8% per year among 
patients who had been assigned to the aspirin 
group. The trial was planned to continue until at 
least 450 events of the primary efficacy outcome 
had occurred. All the analyses were based on the 
intention­to­treat population (which included all 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF SZEGED on November 21, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 378;23 nejm.org June 7, 20182194
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
patients who underwent randomization) unless 
otherwise specified. The annualized event rate 
represents the average number of events per 
participant during a 1­year period.
The rivaroxaban group was compared with 
the aspirin group with the use of a log­rank test, 
and Kaplan–Meier estimates were used to plot 
the cumulative­incidence risk over time. Hazard 
ratios were estimated by the Cox proportional­
hazards model. Secondary efficacy outcomes 
were analyzed with the use of methods similar 
to those used for the primary efficacy analysis. 
A hierarchical analysis plan stipulated that if the 
primary efficacy outcome did not differ signifi­
cantly between treatment groups, secondary out­
comes were to be considered to be exploratory 
and would be reported without claims of statisti­
cal significance. All the reported P values are 
two­sided. Exploratory analyses of prespecified 
subgroups were undertaken with the variables of 
age, sex, geographic region, time from the index 
stroke to randomization, and renal function, but 
the trial was not powered for subgroup compari­
sons. There was no imputation for missing data.
An independent data and safety monitoring 
committee monitored the safety of the patients 
on an ongoing basis. Two formal interim analy­
ses were planned when approximately 50% and 
67% of the first events of the primary efficacy 
outcome had occurred, with the use of a pre­
specified stopping rule that was based on modi­
fied Haybittle–Peto cutoff points for efficacy. 
Details are provided in the statistical analysis 
plan, which is available with the protocol.
R esult s
Participants and Follow-up
After the second interim analysis, on October 5, 
2017, the trial was terminated at the recommen­
dation of the data and safety monitoring com­
mittee owing to an excess risk of bleeding 
among patients assigned to rivaroxaban and an 
absence of an offsetting benefit regarding a re­
duction in the rate of stroke, with little esti­
mated chance of a benefit being found if the 
trial proceeded to its planned completion. All the 
analyses are reported up to that date.
Recruitment began in December 2014 and 
ended in September 2017, with 7213 participants 
being randomly assigned to one of the treatment 
groups (Fig. S1 in the Supplementary Appendix, 
available at NEJM.org). Patients were recruited 
from Europe (43% of the patients were from 
Western Europe and 15% from Eastern Europe), 
East Asia (19%), United States and Canada 
(13%), and Latin America (10%) (Table 1). At the 
time of trial termination, participants had been 
followed for a median of 11 months (range, 1 to 
33; interquartile range, 5 to 17).
The mean age of the patients was 67 years, 
and 62% of the patients were men. In the entire 
cohort, there was a history of hypertension in 
77% of the patients, diabetes mellitus in 25%, 
and previous stroke or transient ischemic attack 
in 18% (Table 1). Patent foramen ovale was diag­
nosed in 5% of the participants (313 of 6883) 
undergoing transthoracic echocardiography and 
in 27% of those (379 of 1382) undergoing trans­
esophageal echocardiography (patients may have 
undergone both procedures). Overall, 7% of the 
participants (259 patients in the rivaroxaban 
group and 275 in the aspirin group) had patent 
foramen ovale. There were no significant differ­
ences in the demographic or clinical character­
istics between the rivaroxaban group and the 
aspirin group. Intracranial arterial imaging was 
performed in 78% of the patients. The median 
duration of cardiac rhythm monitoring before 
randomization was 24 hours (interquartile range, 
24 to 48), with 34% of participants undergoing 
monitoring for 48 hours or longer. The median 
time from the qualifying stroke to randomiza­
tion was 37 days (interquartile range, 14 to 88); 
25% of the patients were entered within 2 weeks. 
The median NIHSS score after the initial stroke 
was 1 (interquartile range, 0 to 2) in each group, 
representing minor residual deficits at trial entry.
The trial drug was discontinued before a pri­
mary outcome event in 15% of the patients in 
the rivaroxaban group and in 12% of those in the 
aspirin group. Protocol­mandated discontinua­
tion of trial medication due to atrial fibrillation 
occurred in 155 patients (2%; 80 patients in the 
rivaroxaban group and 75 in the aspirin group) 
after a median of 5 months (interquartile range, 
2 to 11). A total of 1% of the patients were lost 
to follow­up after a mean (±SD) of 15±9 months, 
and an additional 1% of the patients withdrew 
consent for follow­up after a mean of 5±6 
months. Vital status was available at the end of 
trial for 99% of the patients who had undergone 
randomization and who had not withdrawn con­
sent or been lost to follow­up.
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Outcomes
The primary efficacy outcome of recurrent stroke 
of any type or systemic embolism occurred in 
172 patients in the rivaroxaban group (annual­
ized rate, 5.1%) and in 160 in the aspirin group 
(annualized rate, 4.8%) (hazard ratio, 1.07; 95% 
confidence interval [CI], 0.87 to 1.33; P = 0.52). 
(Table 2 and Fig. 1A). This represented 332 (74%) 
Characteristic
Rivaroxaban Group 
(N = 3609)
Aspirin Group 
(N = 3604)
Age — yr 66.9±9.8 66.9±9.8
Male sex — no. (%) 2232 (62) 2204 (61)
Race — no. (%)†
White only 2612 (72) 2604 (72)
Black only 51 (1) 60 (2)
Asian only 716 (20) 698 (19)
Other 230 (6) 242 (7)
Body-mass index‡ 27.1±4.9 27.3±5.1
Blood pressure — mm Hg
Systolic 135.1±17.0 134.9±16.6
Diastolic 79.0±10.8 78.9±10.8
Statin use after randomization — no. (%) 2815 (78) 2789 (77)
Hypertension — no. (%) 2782 (77) 2803 (78)
Diabetes mellitus — no. (%) 889 (25) 917 (25)
Current tobacco use — no. (%) 756 (21) 728 (20)
Previous stroke or TIA — no. (%) 620 (17) 643 (18)
Geographic region — no. (%)
United States or Canada 461 (13) 457 (13)
Latin America 372 (10) 374 (10)
Western Europe 1541 (43) 1540 (43)
Eastern Europe 560 (16) 558 (15)
East Asia 675 (19) 675 (19)
Qualifying stroke — no./total no. (%)
Single acute lesion on imaging 3231/3606 (90) 3214/3602 (89)
Multiple lesions on imaging 375/3606 (10) 388/3602 (11)
Aspirin use before qualifying stroke — no. (%) 624 (17) 629 (17)
Median NIHSS score at randomization (IQR)§ 1 (0–2) 1 (0–2)
Median modified Rankin scale score at randomization (IQR)¶ 1 (0–2) 1 (0–2)
Median time from qualifying stroke to randomization (IQR) — days 38.0 (15.0–89.0) 36.0 (14.0–86.5)
Intracranial vascular imaging — no. (%)‖ 2821 (78) 2824 (78)
Cardiac rhythm monitoring ≥48 hr — no. (%) 1218 (34) 1217 (34)
*  Plus–minus values are means ±SD. There were no significant differences between the treatment groups with regard to 
any characteristic. Percentages may not total 100 because of rounding. IQR denotes interquartile range, and TIA tran-
sient ischemic attack.
†  Race was reported by the participant. Other race includes unreported data and multiracial.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores representing 
worse neurologic deficits.
¶  Scores on the modified Rankin scale range from 0 to 6, with higher scores representing worse functional deficits.
‖  Computed tomographic angiography was used in 36% of the patients, and transcranial Doppler imaging was the only 
intracranial imaging in 12% of the patients.
Table 1. Characteristics of the Patients at Trial Entry.*
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of the anticipated 450 efficacy events that were 
expected to occur in order for the trial to have 
adequate power. A total of 314 events (95%) were 
ischemic strokes, 158 of which occurred in the 
rivaroxaban group and 156 in the aspirin group 
(hazard ratio, 1.01; 95% CI, 0.81 to 1.26); 15 
events (5%) were hemorrhagic strokes and 3 (1%) 
were systemic emboli. Of the 314 recurrent ische­
mic strokes, 36 (11%) were associated with symp­
toms lasting less than 24 hours but also with 
neuroimaging evidence of brain infarction, and 
5 (2%) could not be classified as ischemic or 
hemorrhagic because brain imaging was not per­
formed. There were 13 hemorrhagic strokes in the 
rivaroxaban group, as compared with 2 in the 
aspirin group. The severity of recurrent ischemic 
strokes as indicated by the modified Rankin 
scale score at hospital discharge was similar in 
the two treatment groups (Fig. S2 in the Supple­
mentary Appendix).
There was no difference in the effect of riva­
roxaban as compared with aspirin with regard to 
the other secondary efficacy outcomes, including 
disabling stroke, myocardial infarction, death 
from any cause, or death from cardiovascular 
causes (Table 2). There was evidence of hetero­
geneity of treatment effect for two prespecified 
exploratory subgroups; patients from East Asia 
(China, Japan, and South Korea) and those with 
an estimated glomerular filtration rate of more 
than 80 ml per minute had lower rates of the 
primary efficacy outcome in the aspirin group 
than in the rivaroxaban group (Fig. 2), but the 
number of events may not have provided ade­
quate power for determining the significance 
of these findings. Efficacy outcomes regarding 
first unrefuted events that occurred between 
randomization and 2 days after receipt of the 
last dose of trial medication are provided in Ta­
ble S1 in the Supplementary Appendix.
Outcome
Rivaroxaban Group 
(N = 3609)
Aspirin Group 
(N = 3604)
Hazard Ratio 
(95% CI)†
no. of patients (annualized rate)
Primary efficacy outcome: any recurrent stroke 
or systemic embolism
172 (5.1) 160 (4.8) 1.07 (0.87–1.33)
Secondary efficacy outcomes
Any recurrent stroke‡ 171 (5.1) 158 (4.7) 1.08 (0.87–1.34)
Ischemic stroke‡ 158 (4.7) 156 (4.7) 1.01 (0.81–1.26)
Hemorrhagic stroke§ 13 (0.4) 2 (0.1) 6.50 (1.47–28.8)
Systemic embolism 1 (<0.1) 2 (0.1) 0.50 (0.05–5.51)
Any recurrent stroke, myocardial infarction, 
death from cardiovascular causes, or  
systemic embolism¶
207 (6.2) 195 (5.8) 1.06 (0.87–1.29)
Any disabling stroke 41 (1.2) 29 (0.8) 1.42 (0.88–2.28)
Myocardial infarction 17 (0.5) 23 (0.7) 0.74 (0.39–1.38)
Death from any cause 65 (1.9) 52 (1.5) 1.26 (0.87–1.81)
Death from cardiovascular causes¶ 34 (1.0) 23 (0.7) 1.48 (0.87–2.52)
*  The annualized event rate represents the average number of events per participant during a 1-year period. Event rates 
are unadjusted.
†  Hazard ratios and 95% confidence intervals were estimated on the basis of age group (<60 years vs. ≥60 years) with 
stratified Cox proportional-hazards models. P = 0.52 for the comparison of the primary outcome.
‡  Data include undefined strokes with no neuroimaging or autopsy (in five patients). Secondary hemorrhagic transforma-
tion is included as ischemic stroke.
§  Atraumatic primary intracerebral hemorrhage (in 13 patients) and subarachnoid hemorrhage (in 2) were included as 
primary outcomes; one additional intracerebral hemorrhage that occurred after an ischemic stroke is not included here 
but is reported with the safety outcomes.
¶  Nine deaths that could not be reliably classified owing to insufficient information were counted as deaths from cardio-
vascular causes.
Table 2. Efficacy Outcomes.*
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Safety Outcomes
Major bleeding occurred in 62 patients in the 
rivaroxaban group (annualized rate, 1.8%), as 
compared with 23 in the aspirin group (annual­
ized rate, 0.7%) (hazard ratio, 2.72; 95% CI, 1.68 
to 4.39; P<0.001) (Table 3 and Fig. 1B). The rate 
of life­threatening or fatal bleeding was signifi­
cantly higher in the rivaroxaban group than in 
the aspirin group (hazard ratio, 2.34; 95% CI, 
1.28 to 4.29; P = 0.004), as were the rates of 
symptomatic intracranial hemorrhage (hazard 
ratio, 4.02; 95% CI, 1.51 to 10.7; P = 0.003) and 
clinically relevant nonmajor bleeding (hazard 
ratio, 1.51; 95% CI, 1.13 to 2.00; P = 0.004) (Ta­
ble 3). Safety outcomes regarding first unrefuted 
events that occurred between randomization and 
2 days after receipt of the last dose of trial 
medication are provided in Table S2 in the Sup­
plementary Appendix.
Discussion
Treatment with rivaroxaban did not result in a 
lower rate of stroke recurrence than aspirin 
among patients with recent ischemic stroke who 
had met criteria for an embolic stroke of undeter­
mined source. Rivaroxaban was also not found 
to have a benefit with regard to the secondary 
efficacy outcomes in this population of patients. 
The risk of recurrent ischemic stroke was approxi­
mately 5% per year in each treatment group.
The incidence of major bleeding was 1.1 per­
centage points per year higher among patients 
in the rivaroxaban group than among those in 
the aspirin group. The rate of intracerebral hem­
orrhage, the most serious category of major 
hemorrhage relevant to stroke, was 0.3% per year 
in the rivaroxaban group versus 0.1% per year in 
the aspirin group. The rate of intracerebral hem­
orrhage among patients in the aspirin group in 
this trial was lower than rates in previously re­
ported cohorts of patients with ischemic stroke.10
All the patients underwent cardiac rhythm 
monitoring for at least 20 hours before random­
ization to screen for covert paroxysmal atrial 
fibrillation lasting 6 minutes or longer. Atrial 
fibrillation was identified during follow­up in 
3% of the patients, at a median of 5 months 
after entry, although systematic screening for 
arrhythmia was not undertaken during the trial 
period. A previous prospective study with con­
tinuous cardiac rhythm monitoring showed that 
12% of patients with cryptogenic stroke had un­
diagnosed atrial fibrillation, often of short dura­
tion.11 Rivaroxaban, including the 15­mg daily 
dose that was used in the current trial, has been 
effective for the prevention of recurrent stroke in 
patients with atrial fibrillation,12­14 and the ab­
sence of an observed lower rate of recurrent 
Figure 1. Cumulative Incidence of the Primary Efficacy Outcome  
and the Primary Safety Outcome, According to Treatment Assignment.
Panel A shows the Kaplan–Meier curves for the time to the first event of the 
primary efficacy outcome, defined as the recurrence of ischemic or hemor-
rhagic stroke or systemic embolism. Panel B shows the Kaplan–Meier curves 
for the time to the first primary safety outcome of major bleeding. Insets 
show the same data on an enlarged y axis.
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Figure 2. Exploratory Analyses of Treatment Effects on the Primary Efficacy Outcome in Prespecified Subgroups.
The trial may be underpowered to assess these subgroups. The annualized event rate represents the average number of events per par-
ticipant during a 1-year period. The size of the square is proportional to the number of participants in the subgroup. Race was reported 
by the participant; other race includes unreported data and multiracial. The body-mass index is the weight in kilograms divided by the 
square of the height in meters. GFR denotes glomerular filtration rate, and TIA transient ischemic attack.
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ischemic stroke with rivaroxaban than with aspirin 
in the current trial suggests that undetected par­
oxysmal atrial fibrillation was not a major cause 
of recurrent stroke.
This trial included patients with patent fora­
men ovale. The end of recruitment was coinci­
dent with the publication of three randomized 
trials that showed a benefit of closure of patent 
foramen ovale, as compared with medical thera­
py, in the treatment of patients with cryptogenic 
stroke and patent foramen ovale.15­17 In our trial, 
it is not known whether patients with patent fora­
men ovale had characteristics that made them at 
risk for stroke. The influence of including pa­
tients with patent foramen ovale (identified in 
7% of the participants) on the outcome of our 
trial is uncertain.
The effect of the 15­mg daily dose of rivar­
oxaban on stroke prevention substantially over­
laps the effect of the 20­mg daily dose.18 The 
latter dose is approved in most countries for the 
prevention of stroke in patients with atrial fibril­
lation. Consequently, the use of the 15­mg dose 
of rivaroxaban in our trial was unlikely to account 
for the lack of benefit in stroke prevention.
Another possible reason for the absence of a 
difference between anticoagulant and antiplate­
let therapy in our trial was that the evaluation 
for eligibility may not have identified strokes due 
to embolism that would be subject to the preven­
tion of recurrent stroke by rivaroxaban. However, 
a comprehensive diagnostic evaluation for a source 
of embolus was required for eligibility. Alterna­
tively, the heterogeneous underlying sources of 
the embolic strokes (arterial, cardiogenic, or para­
doxical) with variation in the composition of 
emboli may have resulted in the trial enrolling a 
population that would not have a response to 
rivaroxaban.
In conclusion, there was no benefit with riva­
roxaban at a daily dose of 15 mg, as compared 
with aspirin at a daily dose of 100 mg, for the 
prevention of stroke recurrence in patients with 
embolic stroke of undetermined source. Patients 
with ischemic stroke who met the eligibility cri­
teria for this trial had a risk of stroke recurrence 
of approximately 5% per year with either treat­
ment. Ongoing randomized trials are testing 
alternative anticoagulants versus aspirin in simi­
lar groups of patients (ClinicalTrials.gov numbers, 
NCT02239120 and NCT02427126).19,20
Supported by Bayer and Janssen Research and Development.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
Outcome
Rivaroxaban Group 
(N = 3609)
Aspirin Group 
(N = 3604)
Hazard Ratio 
(95% CI)† P Value
no. of patients (annualized rate)
Primary safety outcome: ISTH major bleeding‡ 62 (1.8) 23 (0.7) 2.72 (1.68–4.39) <0.001
Secondary safety outcomes
Life-threatening or fatal bleeding 35 (1.0) 15 (0.4) 2.34 (1.28–4.29) 0.004
Clinically relevant nonmajor bleeding 118 (3.5) 79 (2.3) 1.51 (1.13–2.00) 0.004
Symptomatic intracranial hemorrhage§ 20 (0.6) 5 (0.1) 4.02 (1.51–10.7) 0.003
Intracerebral hemorrhage 12 (0.3) 3 (0.1) 4.01 (1.13–14.2) 0.02
Subarachnoid hemorrhage¶ 5 (0.1) 1 (0.0) 5.03 (0.59–43.0) 0.10
Subdural or epidural hematoma¶ 3 (0.1) 2 (0.1) 1.51 (0.25–9.02) 0.65
*  Event rates are unadjusted.
†  Hazard ratios and 95% confidence intervals were estimated on the basis of age group (<60 years vs. ≥60 years) in stratified Cox proportional-
hazards models.
‡  Criteria are from the International Society on Thrombosis and Hemostasis (ISTH).9
§  These events were included as ISTH major bleeding events and life-threatening or fatal bleeding events. Traumatic intracerebral and sub-
arachnoid hemorrhages were included here.
¶  One patient in the aspirin group had both a traumatic subarachnoid hemorrhage and a separate subdural hematoma; both events are in-
cluded here.
Table 3. Safety Outcomes.*
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